PEPTOKING
EN

WADA keeps GLP-1 drugs off its 2027 Prohibited List and continues monitoring

Regulatory

The World Anti-Doping Agency's Executive Committee confirmed that GLP-1 receptor agonists such as semaglutide and tirzepatide will not be banned under the 2027 Prohibited List, which takes effect on January 1, 2027. They stay in WADA's Monitoring Program, which tracks use through testing without sanctions, while the agency gathers data on possible performance effects and misuse. Semaglutide entered the monitoring program in 2024 and tirzepatide in 2026.

Sources

  1. 01Weight-loss drugs avoid Wada banned list for 2027(opens the source in a new tab) BBC Sport via Yahoo Sports
  2. 02WADA publishes 2027 Prohibited List(opens the source in a new tab) Sport Resolutions
  3. 03The Prohibited List(opens the source in a new tab) World Anti-Doping Agency

Peptides involved

  1. ApprovedSemaglutideGLP-1 receptor agonist31
  2. ApprovedTirzepatideDual GIP and GLP-1 receptor agonist39